Overview

Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes

Status:
Unknown status

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection.

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Gemcitabine